Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Unilateral Retinal Vein Occlusion
DOI:
https://doi.org/10.61919/jhrr.v4i3.1248Keywords:
Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, pRNFL Thickness, Central Macular Thickness, Visual AcuityAbstract
Background: Retinal vein occlusion (RVO), including branch (BRVO) and central retinal vein occlusion (CRVO), can lead to vision loss and optic nerve damage. Understanding changes in peripapillary retinal nerve fiber layer (pRNFL) thickness in affected and fellow eyes is crucial for managing these conditions.
Objective: This study evaluated longitudinal changes in pRNFL thickness in eyes with BRVO and CRVO, and their fellow eyes, compared with normal controls.
Methods: In this retrospective case-control study, 68 patients with newly diagnosed unilateral RVO (42 BRVO, 26 CRVO) and 45 controls were included. pRNFL thickness was measured at baseline, 6, 12, and 24 months using spectral-domain optical coherence tomography (SD-OCT) in six sectors. Baseline characteristics like age, gender, hypertension, and diabetes were recorded. Statistical analyses were conducted using SPSS 23.0, with one-way ANOVA, Pearson’s chi-square test, paired t-tests, and repeated-measures ANOVA.
Results: At baseline, BRVO-affected eyes had a global pRNFL thickness of 119.15 ± 17.71 μm, higher than fellow eyes at 104.52 ± 10.46 μm (p < 0.001). CRVO-affected eyes had a baseline pRNFL of 136.04 ± 36.33 μm, compared to 99.93 ± 13.59 μm in fellow eyes (p < 0.001). At 24 months, only the temporal sector in CRVO eyes showed significant pRNFL differences. Global pRNFL thickness in fellow eyes of both BRVO and CRVO groups decreased significantly at 24 months, with no significant change in the control group. Fellow eyes of the CRVO group had significantly lower pRNFL thickness at 12 and 24 months compared to BRVO and control groups.
Conclusion: Both BRVO and CRVO affect pRNFL thickness in fellow eyes, with CRVO showing more susceptibility to damage. This suggests a shared vascular abnormality between RVO and glaucoma, highlighting the importance of careful pRNFL monitoring, particularly in CRVO patients.
Downloads
References
Bandello F, Querques G, Papp A, Dandolo L, Fowst C, Zucchiatti I, et al. Early response to ranibizumab predicts long-term outcomes in diabetic macular edema: a multicenter, 12-month, “real-life” study. Retina. 2014;34(8):1542-9.
Huang Y, Wang S, Zhang Y, Zhang M, Zhao L, Yao X, et al. Comparative study of the effects of conbercept and ranibizumab in diabetic macular edema associated with hard exudates. Curr Eye Res. 2019;44(9):1030-6.
Adhi M, Duker JS. Optical coherence tomography—current and future applications. Curr Opin Ophthalmol. 2013;24(3):213-21.
Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D. Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol. 1982;100(7):1132-40.
Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration and macular edema following central retinal vein occlusion: a review of the clinical trial data. Drugs Today (Barc). 2011;47(8):469-76.
Kim KE, Park KH. Factors contributing to the risk of conversion from ocular hypertension to primary open-angle glaucoma: a perspective review. BMC Ophthalmol. 2013;13(1):1-9.
Hasegawa T, Himori N, Karakawa A, Hara H, Nakano N, Omodaka K, et al. Changes in retinal nerve fiber layer thickness in eyes with branch retinal vein occlusion. Clin Ophthalmol. 2014;8:1973-80.
Lee JY, Yoon YH, Kim HK, Yu HG, Kim JG, Kim JT. A prospective study of ranibizumab in Korean patients with diabetic macular edema. Korean J Ophthalmol. 2014;28(6):466-74.
Shin YI, Nam KY, Lee SE, Jo YJ, Kim JY. Peripapillary vessel density and perfusion in fellow eyes of unilateral retinal vein occlusion: an optical coherence tomography angiography study. Invest Ophthalmol Vis Sci. 2019;60(11):823-9.
Sirakaya E, Kucumen RB. Retinal nerve fiber layer analysis of the fellow eyes in unilateral branch retinal vein occlusion. J Glaucoma. 2014;23(5):341-4.
Heidelberg Engineering. Spectralis® optical coherence tomography. Heidelberg, Germany: Heidelberg Engineering; 2011.
Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: new concepts in pathophysiology and treatment. Cell Biosci. 2014;4(1):1-9.
Osaadon P, Fagan XJ, Lifshitz T, Levy J. A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye (Lond). 2014;28(5):510-20.
Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol. 2008;146(4):496-500.
Shin YI, Nam KY, Lee SE, Jo YJ, Kim JY. Peripapillary vessel density and perfusion in fellow eyes of unilateral retinal vein occlusion: an optical coherence tomography angiography study. Invest Ophthalmol Vis Sci. 2019;60(11):823-9.
Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D. Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol. 1982;100(7):1132-40.
Hayreh SS. Posterior segment ischemic syndrome. Retina. 1983;3(4):247-76.
Yoshida S, Sasaki H, Yamashita H, Motohashi M, Uchida A, Nakamura K, et al. Blood and plasma viscosity in patients with central retinal vein occlusion. Nihon Ganka Gakkai Zasshi. 1997;101(4):401-6.
Quigley HA, Addicks EM, Green WR. Optic nerve damage in human glaucoma: II. The site of injury and susceptibility to damage. Arch Ophthalmol. 1981;99(4):635-49.
Kim SH, Lee EJ, Kim TW. Comparison of structural damage in normal-tension glaucoma with initial parafoveal and peripheral scotomas. Am J Ophthalmol. 2014;157(3):688
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ahmad Hasan Khan Alizai, Dr. Yasir Ahmad, Dr. Fawad Ahmad, Dr. Tahira Afzal Khan, Dr. Muhammad Saad, Rabia Faheem

This work is licensed under a Creative Commons Attribution 4.0 International License.
Public Licensing Terms
This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Under this license:
- You are free to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) for any purpose, including commercial use.
- Attribution must be given to the original author(s) and source in a manner that is reasonable and does not imply endorsement.
- No additional restrictions may be applied that conflict with the terms of this license.
For more details, visit: https://creativecommons.org/licenses/by/4.0/.